Vivani Medical, Inc. (Nasdaq: VANI) entered into a Share Purchase Agreement dated November 15, 2026, with entities affiliated with Gregg Williams, the Company’s Chairman of the board of directors, and Aaron Mendelsohn, a board member. The agreement calls for the sale of 5,049,506 shares of common stock at a purchase price of $1.01 per share. The transaction is expected to generate gross proceeds of approximately $5.1 million for the Company before estimated offering expenses.

The private placement shares are being sold to accredited investors under an exemption from registration under Rule 506 of Regulation D. The closing of the transaction is scheduled for November 23, 2026, subject to customary closing conditions. The shares are being sold at-the-market under the rules of The Nasdaq Stock Market LLC, and no placement agent or investment banking fees were incurred.

The Company intends to use the net proceeds from this offering to fund ongoing research and clinical development of its semaglutide implant, NPM-139, as well as its other product candidates. The funds will also be used for working capital and general corporate purposes. Vivani anticipates that the net proceeds, combined with its existing cash, cash equivalents, and restricted cash, will fund the Company’s operations into the third quarter of 2027.

This financing follows the Company’s announcement on November 12, 2026, regarding positive top-line results from the SLIM-1 clinical trial. SLIM-1 was a four-week, open-label, active-controlled trial involving 20 participants. The trial compared low-dose NPM-139 to the starting dose of Wegovy (0.25 mg/week semaglutide injection). The Company reported that no NPM-139 participants experienced adverse events related to treatment, while five of the 10 Wegovy control group participants experienced gastrointestinal adverse events. No serious adverse events were reported in the study, and implant insertions and removals were completed without complications.